<SEC-DOCUMENT>0001737287-22-000089.txt : 20221129
<SEC-HEADER>0001737287-22-000089.hdr.sgml : 20221129
<ACCEPTANCE-DATETIME>20221129153312
ACCESSION NUMBER:		0001737287-22-000089
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		12
CONFORMED PERIOD OF REPORT:	20221129
ITEM INFORMATION:		Other Events
FILED AS OF DATE:		20221129
DATE AS OF CHANGE:		20221129

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Allogene Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001737287
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				823562771
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38693
		FILM NUMBER:		221432512

	BUSINESS ADDRESS:	
		STREET 1:		210 EAST GRAND AVENUE
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		(650) 457-2700

	MAIL ADDRESS:	
		STREET 1:		210 EAST GRAND AVENUE
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>allo-20221129.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:95b0c2be-68ba-478b-8b88-70b397ab595e,g:0173e9a3-58fb-427b-b9e4-12d5654dbe73,d:d93ebb369c254313a86162a67a26d61d--><html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>allo-20221129</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ie4de01ac93dc47218ac851e369b41796_D20221129-20221129" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmQ5M2ViYjM2OWMyNTQzMTNhODYxNjJhNjdhMjZkNjFkL3NlYzpkOTNlYmIzNjljMjU0MzEzYTg2MTYyYTY3YTI2ZDYxZF80L2ZyYWc6MGEyOTczNmJiNTg4NGNjMmFiNTg3YWY3Y2E1NTNmZDkvdGFibGU6YmIwNTI1ZjI4MTkzNDQ5YWIxNDk5ZDFjMGFhZTdjYzIvdGFibGVyYW5nZTpiYjA1MjVmMjgxOTM0NDlhYjE0OTlkMWMwYWFlN2NjMl8xLTEtMS0xLTQ0NTc5_8246ec3b-d308-4d88-9deb-553941071eba">0001737287</ix:nonNumeric><ix:nonNumeric contextRef="ie4de01ac93dc47218ac851e369b41796_D20221129-20221129" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmQ5M2ViYjM2OWMyNTQzMTNhODYxNjJhNjdhMjZkNjFkL3NlYzpkOTNlYmIzNjljMjU0MzEzYTg2MTYyYTY3YTI2ZDYxZF80L2ZyYWc6MGEyOTczNmJiNTg4NGNjMmFiNTg3YWY3Y2E1NTNmZDkvdGFibGU6YmIwNTI1ZjI4MTkzNDQ5YWIxNDk5ZDFjMGFhZTdjYzIvdGFibGVyYW5nZTpiYjA1MjVmMjgxOTM0NDlhYjE0OTlkMWMwYWFlN2NjMl8yLTEtMS0xLTQ0NTc5_1655f8cc-0623-47d5-b418-d56577e5e54c">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="allo-20221129.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ie4de01ac93dc47218ac851e369b41796_D20221129-20221129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-29</xbrli:startDate><xbrli:endDate>2022-11-29</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="id93ebb369c254313a86162a67a26d61d_1"></div><div style="min-height:33.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">____________________</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ie4de01ac93dc47218ac851e369b41796_D20221129-20221129" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmQ5M2ViYjM2OWMyNTQzMTNhODYxNjJhNjdhMjZkNjFkL3NlYzpkOTNlYmIzNjljMjU0MzEzYTg2MTYyYTY3YTI2ZDYxZF8xL2ZyYWc6OWE3YTRkNzc1M2ZmNDlhMDk4YzIwNjk4ODJjNTFlNGEvdGV4dHJlZ2lvbjo5YTdhNGQ3NzUzZmY0OWEwOThjMjA2OTg4MmM1MWU0YV8xMDU_31ecff08-ec66-456c-b353-ef714211e888">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">____________________</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section&#160;13 or 15(d)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">of the Securities Exchange Act of 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="ie4de01ac93dc47218ac851e369b41796_D20221129-20221129" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmQ5M2ViYjM2OWMyNTQzMTNhODYxNjJhNjdhMjZkNjFkL3NlYzpkOTNlYmIzNjljMjU0MzEzYTg2MTYyYTY3YTI2ZDYxZF8xL2ZyYWc6OWE3YTRkNzc1M2ZmNDlhMDk4YzIwNjk4ODJjNTFlNGEvdGV4dHJlZ2lvbjo5YTdhNGQ3NzUzZmY0OWEwOThjMjA2OTg4MmM1MWU0YV8yNjU_b07dfde8-af59-4102-87db-0bb0329cf424">November 29, 2022</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">_______________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:22pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ie4de01ac93dc47218ac851e369b41796_D20221129-20221129" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmQ5M2ViYjM2OWMyNTQzMTNhODYxNjJhNjdhMjZkNjFkL3NlYzpkOTNlYmIzNjljMjU0MzEzYTg2MTYyYTY3YTI2ZDYxZF8xL2ZyYWc6OWE3YTRkNzc1M2ZmNDlhMDk4YzIwNjk4ODJjNTFlNGEvdGV4dHJlZ2lvbjo5YTdhNGQ3NzUzZmY0OWEwOThjMjA2OTg4MmM1MWU0YV8yOTI_409b228e-ecf0-4517-b643-ac31574859c6">Allogene Therapeutics, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">____________________________</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.283%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie4de01ac93dc47218ac851e369b41796_D20221129-20221129" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmQ5M2ViYjM2OWMyNTQzMTNhODYxNjJhNjdhMjZkNjFkL3NlYzpkOTNlYmIzNjljMjU0MzEzYTg2MTYyYTY3YTI2ZDYxZF8xL2ZyYWc6OWE3YTRkNzc1M2ZmNDlhMDk4YzIwNjk4ODJjNTFlNGEvdGFibGU6MjU1Y2Y1ODYwZTczNGJiNjgyYzJkODc1NGFlZTIxYzYvdGFibGVyYW5nZToyNTVjZjU4NjBlNzM0YmI2ODJjMmQ4NzU0YWVlMjFjNl8wLTAtMS0xLTQ0NTc5_5bff0afa-9acb-4315-8fa7-87c3bf29e4a9">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie4de01ac93dc47218ac851e369b41796_D20221129-20221129" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmQ5M2ViYjM2OWMyNTQzMTNhODYxNjJhNjdhMjZkNjFkL3NlYzpkOTNlYmIzNjljMjU0MzEzYTg2MTYyYTY3YTI2ZDYxZF8xL2ZyYWc6OWE3YTRkNzc1M2ZmNDlhMDk4YzIwNjk4ODJjNTFlNGEvdGFibGU6MjU1Y2Y1ODYwZTczNGJiNjgyYzJkODc1NGFlZTIxYzYvdGFibGVyYW5nZToyNTVjZjU4NjBlNzM0YmI2ODJjMmQ4NzU0YWVlMjFjNl8wLTEtMS0xLTQ0NTc5_5ca06cd6-23d7-4aa6-bcbb-c74745ae6901">001-38693</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie4de01ac93dc47218ac851e369b41796_D20221129-20221129" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmQ5M2ViYjM2OWMyNTQzMTNhODYxNjJhNjdhMjZkNjFkL3NlYzpkOTNlYmIzNjljMjU0MzEzYTg2MTYyYTY3YTI2ZDYxZF8xL2ZyYWc6OWE3YTRkNzc1M2ZmNDlhMDk4YzIwNjk4ODJjNTFlNGEvdGFibGU6MjU1Y2Y1ODYwZTczNGJiNjgyYzJkODc1NGFlZTIxYzYvdGFibGVyYW5nZToyNTVjZjU4NjBlNzM0YmI2ODJjMmQ4NzU0YWVlMjFjNl8wLTItMS0xLTQ0NTc5_5b932858-53a0-4be8-8d57-647ff511263e">82-3562771</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">of incorporation)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Commission</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">File Number)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Identification No.)</span></div></td></tr><tr style="height:5pt"><td colspan="9" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ie4de01ac93dc47218ac851e369b41796_D20221129-20221129" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmQ5M2ViYjM2OWMyNTQzMTNhODYxNjJhNjdhMjZkNjFkL3NlYzpkOTNlYmIzNjljMjU0MzEzYTg2MTYyYTY3YTI2ZDYxZF8xL2ZyYWc6OWE3YTRkNzc1M2ZmNDlhMDk4YzIwNjk4ODJjNTFlNGEvdGV4dHJlZ2lvbjo5YTdhNGQ3NzUzZmY0OWEwOThjMjA2OTg4MmM1MWU0YV8zODA_e3cbb67a-bb15-46d5-a1bc-cd8dbecf5b9b">210 East Grand Avenue</ix:nonNumeric>, <ix:nonNumeric contextRef="ie4de01ac93dc47218ac851e369b41796_D20221129-20221129" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmQ5M2ViYjM2OWMyNTQzMTNhODYxNjJhNjdhMjZkNjFkL3NlYzpkOTNlYmIzNjljMjU0MzEzYTg2MTYyYTY3YTI2ZDYxZF8xL2ZyYWc6OWE3YTRkNzc1M2ZmNDlhMDk4YzIwNjk4ODJjNTFlNGEvdGV4dHJlZ2lvbjo5YTdhNGQ3NzUzZmY0OWEwOThjMjA2OTg4MmM1MWU0YV8zODQ_7471c548-bdec-400f-8d8f-0883c1892736">South San Francisco</ix:nonNumeric>, <ix:nonNumeric contextRef="ie4de01ac93dc47218ac851e369b41796_D20221129-20221129" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmQ5M2ViYjM2OWMyNTQzMTNhODYxNjJhNjdhMjZkNjFkL3NlYzpkOTNlYmIzNjljMjU0MzEzYTg2MTYyYTY3YTI2ZDYxZF8xL2ZyYWc6OWE3YTRkNzc1M2ZmNDlhMDk4YzIwNjk4ODJjNTFlNGEvdGV4dHJlZ2lvbjo5YTdhNGQ3NzUzZmY0OWEwOThjMjA2OTg4MmM1MWU0YV8zODg_d927a179-47f9-40de-aeb2-a69e802d28d2">California</ix:nonNumeric> <ix:nonNumeric contextRef="ie4de01ac93dc47218ac851e369b41796_D20221129-20221129" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmQ5M2ViYjM2OWMyNTQzMTNhODYxNjJhNjdhMjZkNjFkL3NlYzpkOTNlYmIzNjljMjU0MzEzYTg2MTYyYTY3YTI2ZDYxZF8xL2ZyYWc6OWE3YTRkNzc1M2ZmNDlhMDk4YzIwNjk4ODJjNTFlNGEvdGV4dHJlZ2lvbjo5YTdhNGQ3NzUzZmY0OWEwOThjMjA2OTg4MmM1MWU0YV8zOTE_f54e8b35-6398-4784-b7f4-0c8cfd1e8570">94080</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Address of principal executive offices including zip code)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric contextRef="ie4de01ac93dc47218ac851e369b41796_D20221129-20221129" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmQ5M2ViYjM2OWMyNTQzMTNhODYxNjJhNjdhMjZkNjFkL3NlYzpkOTNlYmIzNjljMjU0MzEzYTg2MTYyYTY3YTI2ZDYxZF8xL2ZyYWc6OWE3YTRkNzc1M2ZmNDlhMDk4YzIwNjk4ODJjNTFlNGEvdGV4dHJlZ2lvbjo5YTdhNGQ3NzUzZmY0OWEwOThjMjA2OTg4MmM1MWU0YV81MDc_78c5eb78-89f0-4417-90ca-a4a5b7b51935">650</ix:nonNumeric>) <ix:nonNumeric contextRef="ie4de01ac93dc47218ac851e369b41796_D20221129-20221129" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmQ5M2ViYjM2OWMyNTQzMTNhODYxNjJhNjdhMjZkNjFkL3NlYzpkOTNlYmIzNjljMjU0MzEzYTg2MTYyYTY3YTI2ZDYxZF8xL2ZyYWc6OWE3YTRkNzc1M2ZmNDlhMDk4YzIwNjk4ODJjNTFlNGEvdGV4dHJlZ2lvbjo5YTdhNGQ3NzUzZmY0OWEwOThjMjA2OTg4MmM1MWU0YV81MTE_c7973ae2-374f-4402-aa51-fd96aa589289">457-2700</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Former name or former address, if changed since last report.)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">________________________________</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:3.738%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.732%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.130%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie4de01ac93dc47218ac851e369b41796_D20221129-20221129" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmQ5M2ViYjM2OWMyNTQzMTNhODYxNjJhNjdhMjZkNjFkL3NlYzpkOTNlYmIzNjljMjU0MzEzYTg2MTYyYTY3YTI2ZDYxZF8xL2ZyYWc6OWE3YTRkNzc1M2ZmNDlhMDk4YzIwNjk4ODJjNTFlNGEvdGFibGU6Y2Q5MzQ3OGYwMDIxNGUyNTkxZjAyOWNiZGRkZmNjMDcvdGFibGVyYW5nZTpjZDkzNDc4ZjAwMjE0ZTI1OTFmMDI5Y2JkZGRmY2MwN18wLTEtMS0xLTQ0NTc5_e49338ec-972d-4032-8faf-61e58e35e217">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie4de01ac93dc47218ac851e369b41796_D20221129-20221129" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmQ5M2ViYjM2OWMyNTQzMTNhODYxNjJhNjdhMjZkNjFkL3NlYzpkOTNlYmIzNjljMjU0MzEzYTg2MTYyYTY3YTI2ZDYxZF8xL2ZyYWc6OWE3YTRkNzc1M2ZmNDlhMDk4YzIwNjk4ODJjNTFlNGEvdGFibGU6Y2Q5MzQ3OGYwMDIxNGUyNTkxZjAyOWNiZGRkZmNjMDcvdGFibGVyYW5nZTpjZDkzNDc4ZjAwMjE0ZTI1OTFmMDI5Y2JkZGRmY2MwN18xLTEtMS0xLTQ0NTc5_de100c34-1146-4762-b95c-3d88775c75dd">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie4de01ac93dc47218ac851e369b41796_D20221129-20221129" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmQ5M2ViYjM2OWMyNTQzMTNhODYxNjJhNjdhMjZkNjFkL3NlYzpkOTNlYmIzNjljMjU0MzEzYTg2MTYyYTY3YTI2ZDYxZF8xL2ZyYWc6OWE3YTRkNzc1M2ZmNDlhMDk4YzIwNjk4ODJjNTFlNGEvdGFibGU6Y2Q5MzQ3OGYwMDIxNGUyNTkxZjAyOWNiZGRkZmNjMDcvdGFibGVyYW5nZTpjZDkzNDc4ZjAwMjE0ZTI1OTFmMDI5Y2JkZGRmY2MwN18yLTEtMS0xLTQ0NTc5_194d4503-0063-424e-9d17-09042ad7734b">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie4de01ac93dc47218ac851e369b41796_D20221129-20221129" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmQ5M2ViYjM2OWMyNTQzMTNhODYxNjJhNjdhMjZkNjFkL3NlYzpkOTNlYmIzNjljMjU0MzEzYTg2MTYyYTY3YTI2ZDYxZF8xL2ZyYWc6OWE3YTRkNzc1M2ZmNDlhMDk4YzIwNjk4ODJjNTFlNGEvdGFibGU6Y2Q5MzQ3OGYwMDIxNGUyNTkxZjAyOWNiZGRkZmNjMDcvdGFibGVyYW5nZTpjZDkzNDc4ZjAwMjE0ZTI1OTFmMDI5Y2JkZGRmY2MwN18zLTEtMS0xLTQ0NTc5_dc428830-b742-49a2-bbf9-18ea65a2356a">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:31.744%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.744%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.746%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Symbol(s)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name&#160;of&#160;each&#160;exchange</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">on&#160;which&#160;registered</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie4de01ac93dc47218ac851e369b41796_D20221129-20221129" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmQ5M2ViYjM2OWMyNTQzMTNhODYxNjJhNjdhMjZkNjFkL3NlYzpkOTNlYmIzNjljMjU0MzEzYTg2MTYyYTY3YTI2ZDYxZF8xL2ZyYWc6OWE3YTRkNzc1M2ZmNDlhMDk4YzIwNjk4ODJjNTFlNGEvdGFibGU6NTBlMzczODQxYTg3NDU0Y2EzY2Q0NzczZDRmYTgzOWQvdGFibGVyYW5nZTo1MGUzNzM4NDFhODc0NTRjYTNjZDQ3NzNkNGZhODM5ZF8xLTAtMS0xLTQ0NTc5_a81525e1-70e7-419d-8590-8055f9580a66">Common&#160;Stock,&#160;$0.001&#160;par&#160;value&#160;per&#160;share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie4de01ac93dc47218ac851e369b41796_D20221129-20221129" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmQ5M2ViYjM2OWMyNTQzMTNhODYxNjJhNjdhMjZkNjFkL3NlYzpkOTNlYmIzNjljMjU0MzEzYTg2MTYyYTY3YTI2ZDYxZF8xL2ZyYWc6OWE3YTRkNzc1M2ZmNDlhMDk4YzIwNjk4ODJjNTFlNGEvdGFibGU6NTBlMzczODQxYTg3NDU0Y2EzY2Q0NzczZDRmYTgzOWQvdGFibGVyYW5nZTo1MGUzNzM4NDFhODc0NTRjYTNjZDQ3NzNkNGZhODM5ZF8xLTItMS0xLTQ0NTc5_e259b2cb-ce97-4933-95f3-8b924413583f">ALLO</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie4de01ac93dc47218ac851e369b41796_D20221129-20221129" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmQ5M2ViYjM2OWMyNTQzMTNhODYxNjJhNjdhMjZkNjFkL3NlYzpkOTNlYmIzNjljMjU0MzEzYTg2MTYyYTY3YTI2ZDYxZF8xL2ZyYWc6OWE3YTRkNzc1M2ZmNDlhMDk4YzIwNjk4ODJjNTFlNGEvdGFibGU6NTBlMzczODQxYTg3NDU0Y2EzY2Q0NzczZDRmYTgzOWQvdGFibGVyYW5nZTo1MGUzNzM4NDFhODc0NTRjYTNjZDQ3NzNkNGZhODM5ZF8xLTQtMS0xLTQ0NTc5_d230ba86-6ddb-4d89-9a7c-4c220eb16c1a">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#160;230.405 of this chapter) or Rule 12b&#8211;2 of the Securities Exchange Act of 1934 (&#167;&#160;240.12b&#8211;2 of this chapter).</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company <ix:nonNumeric contextRef="ie4de01ac93dc47218ac851e369b41796_D20221129-20221129" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmQ5M2ViYjM2OWMyNTQzMTNhODYxNjJhNjdhMjZkNjFkL3NlYzpkOTNlYmIzNjljMjU0MzEzYTg2MTYyYTY3YTI2ZDYxZF8xL2ZyYWc6OWE3YTRkNzc1M2ZmNDlhMDk4YzIwNjk4ODJjNTFlNGEvdGV4dHJlZ2lvbjo5YTdhNGQ3NzUzZmY0OWEwOThjMjA2OTg4MmM1MWU0YV8xMTQ2_a4f81d39-481a-4a86-905a-f9947ec144cb">&#9744;</ix:nonNumeric></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;&#9744;</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="id93ebb369c254313a86162a67a26d61d_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;8.01&#160;&#160;&#160;&#160;Other Events.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 29, 2022, Allogene Therapeutics, Inc. (the &#8220;Company&#8221;), in collaboration with Les Laboratoires Servier SAS and Institut de Recherches Internationales Servier SAS, an independent international pharmaceutical company (together, &#8220;Servier&#8221;), announced results from the Phase 1 ALPHA trial of ALLO-501 and from the Phase 1 ALPHA2 trial of ALLO-501A in relapsed/refractory (&#8220;r/r&#8221;) large B-cell lymphoma (&#8220;LBCL&#8221;) at the Company&#8217;s R&amp;D Showcase. The Company also announced results from the Phase 1 UNIVERSAL trial of ALLO-715 in r/r multiple myeloma (&#8220;MM&#8221;), results from the Phase 1 TRAVERSE trial of ALLO-316 in advanced or metastatic clear cell renal cell carcinoma (&#8220;RCC&#8221;) and certain research initiatives.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Results from the Phase 1 ALLO-501 ALPHA Trial and the Phase 1 ALLO-501A ALPHA2 Trial</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company conducted an extensive Phase 1 program designed to evaluate and optimize all aspects of its lead product candidate, including the dose and schedule of ALLO-501A and ALLO-647. In addition, following a review of the Phase 1 program, the Company determined that its Alloy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufacturing process was associated with robust performance. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alloy is being deployed in the ongoing Phase 2 ALPHA2 trial. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A single infusion of CAR+ cells with FCA90 lymphodepletion regimen consisting of fludarabine (30 mg/m2/day x 3 days) and cyclophosphamide (300 mg/m2/day x 3 days) (standard flu/cy) plus 90 mg of ALLO-647 (&#8220;Single Dose FCA90&#8221;) was deemed preferrable to two infusions of CAR+ cells (&#8220;Consolidation Regimen&#8221;). In the Consolidation Regimen, ALLO-647 dosing was split into 60 mg and 30 mg prior to the first and second infusion of CAR+ cells. This finding underscores the importance of optimizing lymphodepletion in allogeneic cell therapy. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data from the Phase 1 trials of ALLO-501 and ALLO-501A support the ability of a single administration of CAR T cells to generate deep and durable responses. As of the October 25, 2022 data cutoff, 33 autologous CAR T na&#239;ve patients with r/r LBCL were treated with Alloy process material. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ninety-two percent (92%) of all enrolled patients received investigational product with 100% of infused product manufactured and released as per product specifications. Patients were able to initiate treatment within two days of enrollment. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Responses in the ALPHA trials were overall durable. Of the nine patients treated with Alloy process material who achieved a complete response (&#8220;CR&#8221;) at six months, eight remain in remission with the longest CR ongoing at 26+ months. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among 12 patients treated with the Single Dose FCA90 regimen, the overall response rate (&#8220;ORR&#8221;) was 67% and 58% achieved CRs. Among the eight patients in the Single Dose FCA90 cohort who had the opportunity to be followed for six months or more, four (50%) were in CR at both six and 12 months.   </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.309%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alloy Process</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All LBCL<br/>(n = 48)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All Alloy<br/>(n=33)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidation Regimen (n=15)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Single Dose FCA90<br/>(n=12)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Overall Response Rate (ORR), n (%)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 (48)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 (58)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 (53)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8 (67)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Complete Response (CR), n (%)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 (29)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 (42)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 (40)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7 (58)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 Month CR Rate, n (%)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 (23)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 (31)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 (33)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4 (50)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 Month CR Rate, n (%)</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 (21)</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 (28)</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 (27)</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4 (50)</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ALPHA Phase 1 trials demonstrated a manageable safety profile. There were no observed dose limiting toxicities (&#8220;DLTs&#8221;) or graft-vs-host disease (&#8220;GvHD&#8221;). Among patients treated with Single Dose FCA90, there was no Grade 3+ cytokine release syndrome (&#8220;CRS&#8221;) or neurotoxicity. One patient (8%) experienced a Grade 3+ infection and two (17%) experienced prolonged Grade 3+ cytopenia. As previously reported, one Grade 5 event occurred. No new Grade 5 events have occurred.   </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="18" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Alloy Process</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="6" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All LBCL <br/>(n=48)</span></td><td colspan="6" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All Alloy<br/>(n=33)</span></td><td colspan="6" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidation Regimens<br/>(n=15)</span></td><td colspan="6" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Single Dose <br/>(n=12)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adverse Events of Interest</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All Grs<br/>n (%)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gr 3+<br/>n (%)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All Grs<br/>n (%)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gr 3+<br/>n (%)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All Grs<br/>n (%)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gr 3+<br/>n (%)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All Grs<br/>n (%)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gr 3+<br/>n (%)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CRS</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 (23)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 (24)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 (20)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 (33)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neurotoxicity</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 (31)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 (6)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 (36)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 (6)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 (40)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 (13)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 (33)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ICANS</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GvHD</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infection</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 (52)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 (19)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 (58)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 (15)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 (53)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 (20)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 (67) </span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 (8)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prolonged Gr3+ cytopenia</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 (19)</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 (12)</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 (13)</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 (17)</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has initiated the industry&#8217;s first potentially pivotal Phase 2 allogeneic CAR T clinical trial with ALLO-501A in patients with r/r LBCL. The single-arm Phase 2 ALPHA2 trial will utilize a single dose of ALLO-501A (120 million CAR+ cells) with the FCA90 lymphodepletion regimen. The ALPHA2 trial will enroll approximately 100 patients who have received at least two prior lines of therapy and have not received prior anti-CD19 therapy. The primary endpoint of this trial is ORR, and the key secondary endpoint is duration of response (&#8220;DOR&#8221;).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Results from the Phase 1 UNIVERSAL Trial</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Phase 1 UNIVERSAL study is a dose escalation trial in patients with heavily pretreated r/r MM. Dose expansion cohorts comprised of a single dose of ALLO-715 (320 million CAR+ cells) and either FCA39 lymphodepletion (standard flu/cy </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">plus 39 mg of ALLO-647) or FCA60 lymphodepletion (standard flu/cy plus 60 mg of ALLO-647) </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">demonstrated substantial and durable responses. Importantly, 92% of all enrolled patients received investigational product with 100% of infused product manufactured and released as per product specifications. Patients were able to initiate treatment within five days of enrollment and no bridging therapy was required.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through a median follow-up of 14.8 months as of the October 11, 2022 data cutoff, the ORR was 67% in the FCA60 cohort and the very good partial response or better rate (&#8220;VGPR+&#8221;) was 42%. All VGPR+ were minimal residual disease (&#8220;MRD&#8221;) negative. The median duration of response was 9.2 months, with the longest ongoing response at 24 months</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.456%"><tr><td style="width:1.0%"></td><td style="width:35.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.176%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.178%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expansion Cohorts</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LD Regimen</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total<br/>(n=23*)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FCA39<br/>(n=11)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FCA60<br/>(n=12)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ORR*, n (%)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 (65)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 (64)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 (67)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VGPR+ rate, n (%)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11(48)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 (54)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 (42)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CR/sCR rate, n (%)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 (22)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 (27)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 (17)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Median DOR</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">* Five patients with best responses ranging from stable disease to partial response are not included due to limited follow-up.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Safety profile was manageable with low-grade and reversible neurotoxicity and no GvHD. In the expansion cohorts, there was low use of tocilizumab (32%) and steroids (25%). Eight patients (29%) experienced Grade 3+ infections and prolonged Grade 3+ cytopenias. As previously reported, one Grade 5 event occurred in the expansion cohorts and no new Grade 5 events have occurred.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.912%"><tr><td style="width:1.0%"></td><td style="width:45.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.026%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.928%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="6" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expansion Cohorts<br/>(N=28)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adverse Events of Interest</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All Grades<br/>n (%)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grade 3+<br/>n (%)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CRS</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 (68)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 (4)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neurotoxicity</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 (61)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ICANS</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 (4)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GvHD</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infection</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 (68)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 (29)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prolonged Gr3+ Cytopenia</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 (29)</span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is planning a potentially pivotal Phase 2 trial for ALLO-715 in r/r MM, including planned regulatory discussions, optimizing the manufacturing process and transitioning manufacturing of ALLO-715 to the Company&#8217;s own manufacturing facility, Cell Forge 1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Company&#8217;s BCMA strategy, the Company has also been conducting a Phase 1 clinical trial (the &#8220;IGNITE trial&#8221;) of ALLO-605, the first product candidate to incorporate TurboCAR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technology. TurboCAR technology allows cytokine signaling to be engineered selectively into CAR T cells and has shown the ability to improve the potency and persistence of the cells and to delay exhaustion of the cells in preclinical models. The Company is currently reviewing the manufacturing process for ALLO-605 and is not enrolling patients in the IGNITE trial at this time.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Results from the Phase 1 TRAVERSE Trial</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ALLO-316, the Company&#8217;s first allogeneic CAR T cell (&#8220;AlloCAR T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) candidate for solid tumors, targets CD70, an antigen expressed on RCC and other malignancies. The ongoing Phase 1 TRAVERSE study is enrolling patients with advanced or metastatic RCC who have progressed on or intolerant to standard therapies, including an immune checkpoint inhibitor and a VEGF-targeting therapy. Initial data from this trial has demonstrated the promise of an AlloCAR T to treat CD70 expressing RCC with ALLO-316 inducing anti-tumor activity with deepening responses over time. Observed anti-tumor activity was largely confined to patients with CD70 expressing tumors. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the data extract date of November 17, 2022, in the nine patients with tumors known to express CD70, the disease control rate (&#8220;DCR&#8221;) was 100% including three patients who achieved a partial response (&#8220;PR&#8221;) (two confirmed and one unconfirmed, with the longest response lasting until month eight). Cell expansion in patients with CD70 positive disease was robust, and there was a trend toward greater tumor shrinkage in patients with the highest levels of CD70 expression.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.912%"><tr><td style="width:1.0%"></td><td style="width:45.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.026%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.928%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All Patients<br/>(n=17)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CD70+ Patients<br/>(n=9)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ORR, n (%)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 (18)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3 (33)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DCR, n (%)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 (82)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9 (100)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PR, n (%)</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 (18)</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3 (33)</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ALLO-316 has demonstrated a generally manageable safety profile with no GvHD. One dose limiting toxicity of liver enzyme elevation occurred in the second dose level. Grade 3+ prolonged cytopenia was observed in three patients (18%). CRS was all low grade with the exception of one case of Grade 3 CRS. Neurotoxicity was low grade, reversible and seen in only three patients (18%).  No grade 5 events have occurred.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.912%"><tr><td style="width:1.0%"></td><td style="width:45.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.026%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.928%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="6" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All Patients<br/>(n=17)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All Grades<br/>n (%)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gr 3+<br/>n (%)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CRS</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 (65)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 (6)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neurotoxicity</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 (18)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ICANS</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GvHD</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infection</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 (53)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 (30)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prolonged Gr3+ Cytopenia</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 (18)</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has developed an investigational </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> companion diagnostic (&#8220;IVD&#8221;) assay designed for use in determining CD70 expression levels for patient selection in TRAVERSE. The trial is now deploying the IVD assay for the purposes of identifying patients most likely to benefit from ALLO-316. TRAVERSE will continue to explore varying cell dose and lymphodepletion regimens, including FC and FCA in CD70 positive RCC patients. Subject to ongoing results in the TRAVERSE trial, the Company may investigate ALLO-316 for other CD70 expressing solid tumors and hematologic indications.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research Update</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has pursued an integrated strategy within Research and Development aimed at matching technology with insights obtained from the clinic to create solutions designed to advance patient outcomes.  One of these is Dagger</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a proprietary technology designed to control rejection of AlloCAR T cells by the host immune cells. This technology deploys a CD70 CAR on AlloCAR T cells in an effort to recognize and deplete CD70 positive alloreactive host T cells. The Company plans to deploy the Dagger technology in the next generation of AlloCAR T products to delay rejection, while inducing CAR T proliferation and increased tumor killing.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s AlloCAR T programs utilize Cellectis technologies. ALLO-501 and ALLO-501A are anti-CD19 products being jointly developed under a collaboration agreement between Servier and the Company based on an exclusive license granted by Cellectis to Servier. Servier grants to the Company exclusive rights to ALLO-501 and ALLO-501A in the U.S. ALLO-715 and ALLO-605 target BCMA, and ALLO-316 targets CD70. The Company has an exclusive license to the Cellectis technology for allogeneic products directed at BCMA and CD70 and holds all global development and commercial rights for these investigational candidates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The below risk factor supplements the risk factors described in Item 1A of our Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2022 (&#8220;Form 10-Q&#8221;). The following risk factor should be read in conjunction with the risk factors described in our Form 10-Q.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Phase 1 data from our clinical trials is limited and may change as more patient data become available or may not be validated in any future or advanced clinical trial.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Phase 1 results are preliminary in nature and should not be viewed as predictive of ultimate success. It is possible that such results will not continue or may not be repeated in any clinical trial of our product candidates. For instance, our Phase 2 ALPHA2 trial design is based on a data from a limited number of patients treated with from various doses of ALLO-501 or ALLO-501A manufactured using the Alloy process, and the larger Phase 2 ALPHA2 trial may not repeat the Phase 1 results. In addition, the ALPHA trials indicated that the manufacturing process can impact clinical outcomes. The manufacturing runs we have completed and tested in the clinic are limited across our product candidates and we may fail to identify optimized manufacturing processes, including for ALLO-715 and ALLO-605, or ultimately be able to manufacture our product candidates with consistent and reproducible product characteristics.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, initial, interim and preliminary data should be viewed with caution until the final data are available. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cautionary Note on Forward-Looking Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Form 8-K contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Form 8-K may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the timing and ability to progress the ALPHA2, UNIVERSAL, and TRAVERSE trials; the likelihood of success of the Phase 2 ALPHA2 trial, which is based on limited data from the Phase 1 ALPHA trials across two different product candidates and various doses of ALLO-501 or ALLO-501A; advancing to a Phase 2 UNIVERSAL trial; broadening the TRAVERSE trial or ALLO-316 program to other indications; clinical outcomes, which may materially change as more patient data become available; trial designs; the ability to manufacture AlloCAR T products, including with the Alloy process, with consistent and reproducible product characteristics; the ability to enroll patients in clinical trials; the design and potential benefits of the Company&#8217;s Dagger technology; the potential for the Company&#8217;s product candidates to be approved; and the potential benefits of AlloCAR T products. Various factors may cause differences between the Company&#8217;s expectations and actual results as discussed in greater detail in the Company&#8217;s filings with the SEC, including without limitation in this Form 8-K and under the &#8220;Risk Factors&#8221; heading of its Form 10-Q for the quarter ended September 30, 2022. Any forward-looking statements that are made in this Form 8-K speak only as of the date of this Form 8-K. The Company assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this Form 8-K.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="id93ebb369c254313a86162a67a26d61d_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:57.025%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.621%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.955%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ALLOGENE THERAPEUTICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ David Chang, M.D., Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David Chang, M.D., Ph.D.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, Chief Executive Officer</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated: November 29, 2022</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>2
<FILENAME>allo-20221129.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:95b0c2be-68ba-478b-8b88-70b397ab595e,g:0173e9a3-58fb-427b-b9e4-12d5654dbe73-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:allo="http://allogene.com/20221129" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://allogene.com/20221129">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="allo-20221129_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="allo-20221129_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://allogene.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>3
<FILENAME>allo-20221129_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:95b0c2be-68ba-478b-8b88-70b397ab595e,g:0173e9a3-58fb-427b-b9e4-12d5654dbe73-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityCentralIndexKey_e85bc73d-8dc2-416c-aece-484466033fec_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_43ac7068-5d51-4837-83e4-9d0ead6789df_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_48ea7535-832d-4a8d-9974-a6e06ed9c7e5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_fbe07d6d-7a2e-4a81-be16-18fbe6c4a053_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_3abc6c79-84a6-4686-99fa-0412dc2d9998_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_ed8806a8-e0e2-46c7-8f61-13e2749e08d6_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_9f7524c3-215e-47a0-a89f-af268855fe77_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_cd3c9bcc-2011-469b-8f97-f3e5f347782b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_7c41ac19-7aec-4943-b882-8ee86e49e8b0_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_2eb3fb46-4a65-4ac4-83ac-bbade025e1de_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_de38e215-0c02-4a5d-9bc8-229ec71323c1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_11e1b851-0264-4056-9a66-c6000e903b08_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_4a8318ca-ce6d-4b8a-9487-cfa1a69a08cb_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_6012be02-64f3-44cd-afd0-73ce674bd6c1_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover page.</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_ba69d5c0-b359-437f-a796-0f11c2f14852_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_e81736b5-5413-46e4-b2fb-08f04f5d4246_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_186e402f-1086-4174-9775-76d95e7a4da5_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_29ac9daf-d694-461f-87eb-6e6dbd4ffd27_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_13ddfe33-0819-41ab-8c6b-683428692768_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_79fca1b4-d047-4a84-bbd6-2924b1e91197_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_c6d32f5b-4451-4589-8160-df0640ed71ef_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_a7de850d-b9c9-44d8-8034-75a62f27ce06_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_7f5cb8d9-14df-42e4-921e-202493730321_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>4
<FILENAME>allo-20221129_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:95b0c2be-68ba-478b-8b88-70b397ab595e,g:0173e9a3-58fb-427b-b9e4-12d5654dbe73-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://allogene.com/role/Cover" xlink:type="simple" xlink:href="allo-20221129.xsd#Cover"/>
  <link:presentationLink xlink:role="http://allogene.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_9d7e2e46-ed6e-4d66-a8b2-e4b63356b16b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_42be2916-768e-4768-afc6-67bad8c51608" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d7e2e46-ed6e-4d66-a8b2-e4b63356b16b" xlink:to="loc_dei_DocumentType_42be2916-768e-4768-afc6-67bad8c51608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_d5a3373a-ebc2-4aff-9996-0cc57276d788" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d7e2e46-ed6e-4d66-a8b2-e4b63356b16b" xlink:to="loc_dei_DocumentPeriodEndDate_d5a3373a-ebc2-4aff-9996-0cc57276d788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_c66d897c-be13-4db9-ac71-c0ac0ccdc631" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d7e2e46-ed6e-4d66-a8b2-e4b63356b16b" xlink:to="loc_dei_EntityRegistrantName_c66d897c-be13-4db9-ac71-c0ac0ccdc631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_f56557dd-16ca-404f-b9e0-06d2baed0a5e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d7e2e46-ed6e-4d66-a8b2-e4b63356b16b" xlink:to="loc_dei_EntityIncorporationStateCountryCode_f56557dd-16ca-404f-b9e0-06d2baed0a5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_c105e454-5600-4ba5-bf39-0da52f870f62" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d7e2e46-ed6e-4d66-a8b2-e4b63356b16b" xlink:to="loc_dei_EntityFileNumber_c105e454-5600-4ba5-bf39-0da52f870f62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_1247fcaa-adb0-464d-90a7-3def7c3dcd82" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d7e2e46-ed6e-4d66-a8b2-e4b63356b16b" xlink:to="loc_dei_EntityTaxIdentificationNumber_1247fcaa-adb0-464d-90a7-3def7c3dcd82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_8a89b64d-085f-477a-b2ef-e130607178c1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d7e2e46-ed6e-4d66-a8b2-e4b63356b16b" xlink:to="loc_dei_EntityAddressAddressLine1_8a89b64d-085f-477a-b2ef-e130607178c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_d77fb3d4-9f14-46e2-a3bb-1c65fb06104e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d7e2e46-ed6e-4d66-a8b2-e4b63356b16b" xlink:to="loc_dei_EntityAddressCityOrTown_d77fb3d4-9f14-46e2-a3bb-1c65fb06104e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_c6350607-98c9-4898-a4f8-045b51a119f5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d7e2e46-ed6e-4d66-a8b2-e4b63356b16b" xlink:to="loc_dei_EntityAddressStateOrProvince_c6350607-98c9-4898-a4f8-045b51a119f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_ec05cad4-ec7d-4439-8621-c5f0ba951364" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d7e2e46-ed6e-4d66-a8b2-e4b63356b16b" xlink:to="loc_dei_EntityAddressPostalZipCode_ec05cad4-ec7d-4439-8621-c5f0ba951364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_48b02c61-12f6-4d6f-80fb-543dff71e6a0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d7e2e46-ed6e-4d66-a8b2-e4b63356b16b" xlink:to="loc_dei_CityAreaCode_48b02c61-12f6-4d6f-80fb-543dff71e6a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_5d37fa30-7c8b-4f4f-b7b3-5ca13f409e77" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d7e2e46-ed6e-4d66-a8b2-e4b63356b16b" xlink:to="loc_dei_LocalPhoneNumber_5d37fa30-7c8b-4f4f-b7b3-5ca13f409e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_79d25c1b-9284-4c65-a904-3ecb6a859493" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d7e2e46-ed6e-4d66-a8b2-e4b63356b16b" xlink:to="loc_dei_WrittenCommunications_79d25c1b-9284-4c65-a904-3ecb6a859493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_65569b23-aa09-4b99-800a-ba40ee16fad2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d7e2e46-ed6e-4d66-a8b2-e4b63356b16b" xlink:to="loc_dei_SolicitingMaterial_65569b23-aa09-4b99-800a-ba40ee16fad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_ea5dd317-4974-461b-ab71-6d20c5af88be" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d7e2e46-ed6e-4d66-a8b2-e4b63356b16b" xlink:to="loc_dei_PreCommencementTenderOffer_ea5dd317-4974-461b-ab71-6d20c5af88be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_f472335f-b8e8-4d33-a06e-dd5461155de3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d7e2e46-ed6e-4d66-a8b2-e4b63356b16b" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_f472335f-b8e8-4d33-a06e-dd5461155de3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_25f7764e-3633-44ba-89d2-8b5a10379301" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d7e2e46-ed6e-4d66-a8b2-e4b63356b16b" xlink:to="loc_dei_Security12bTitle_25f7764e-3633-44ba-89d2-8b5a10379301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_1ab9ac76-8a28-47e5-946e-cb77f3cffecd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d7e2e46-ed6e-4d66-a8b2-e4b63356b16b" xlink:to="loc_dei_TradingSymbol_1ab9ac76-8a28-47e5-946e-cb77f3cffecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_e72fb4e9-c8ef-4f34-ae75-7767ac2e6481" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d7e2e46-ed6e-4d66-a8b2-e4b63356b16b" xlink:to="loc_dei_SecurityExchangeName_e72fb4e9-c8ef-4f34-ae75-7767ac2e6481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_483ab610-e2a5-443d-99fa-925e97cfe8e9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d7e2e46-ed6e-4d66-a8b2-e4b63356b16b" xlink:to="loc_dei_EntityEmergingGrowthCompany_483ab610-e2a5-443d-99fa-925e97cfe8e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_2e717505-e8a1-4f5b-b512-3ceee05dda1f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d7e2e46-ed6e-4d66-a8b2-e4b63356b16b" xlink:to="loc_dei_EntityCentralIndexKey_2e717505-e8a1-4f5b-b512-3ceee05dda1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_a2474f23-85fb-4c72-a5dd-69bf682afe48" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d7e2e46-ed6e-4d66-a8b2-e4b63356b16b" xlink:to="loc_dei_AmendmentFlag_a2474f23-85fb-4c72-a5dd-69bf682afe48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>5
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140334470770096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Nov. 29, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov. 29,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Allogene Therapeutics, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38693<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-3562771<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">210 East Grand Avenue<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South San Francisco<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">457-2700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common&#160;Stock,&#160;$0.001&#160;par&#160;value&#160;per&#160;share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ALLO<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001737287<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>allo-20221129_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="allo-20221129.xsd" xlink:type="simple"/>
    <context id="ie4de01ac93dc47218ac851e369b41796_D20221129-20221129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
        </entity>
        <period>
            <startDate>2022-11-29</startDate>
            <endDate>2022-11-29</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="ie4de01ac93dc47218ac851e369b41796_D20221129-20221129"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5M2ViYjM2OWMyNTQzMTNhODYxNjJhNjdhMjZkNjFkL3NlYzpkOTNlYmIzNjljMjU0MzEzYTg2MTYyYTY3YTI2ZDYxZF80L2ZyYWc6MGEyOTczNmJiNTg4NGNjMmFiNTg3YWY3Y2E1NTNmZDkvdGFibGU6YmIwNTI1ZjI4MTkzNDQ5YWIxNDk5ZDFjMGFhZTdjYzIvdGFibGVyYW5nZTpiYjA1MjVmMjgxOTM0NDlhYjE0OTlkMWMwYWFlN2NjMl8xLTEtMS0xLTQ0NTc5_8246ec3b-d308-4d88-9deb-553941071eba">0001737287</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="ie4de01ac93dc47218ac851e369b41796_D20221129-20221129"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5M2ViYjM2OWMyNTQzMTNhODYxNjJhNjdhMjZkNjFkL3NlYzpkOTNlYmIzNjljMjU0MzEzYTg2MTYyYTY3YTI2ZDYxZF80L2ZyYWc6MGEyOTczNmJiNTg4NGNjMmFiNTg3YWY3Y2E1NTNmZDkvdGFibGU6YmIwNTI1ZjI4MTkzNDQ5YWIxNDk5ZDFjMGFhZTdjYzIvdGFibGVyYW5nZTpiYjA1MjVmMjgxOTM0NDlhYjE0OTlkMWMwYWFlN2NjMl8yLTEtMS0xLTQ0NTc5_1655f8cc-0623-47d5-b418-d56577e5e54c">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="ie4de01ac93dc47218ac851e369b41796_D20221129-20221129"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5M2ViYjM2OWMyNTQzMTNhODYxNjJhNjdhMjZkNjFkL3NlYzpkOTNlYmIzNjljMjU0MzEzYTg2MTYyYTY3YTI2ZDYxZF8xL2ZyYWc6OWE3YTRkNzc1M2ZmNDlhMDk4YzIwNjk4ODJjNTFlNGEvdGV4dHJlZ2lvbjo5YTdhNGQ3NzUzZmY0OWEwOThjMjA2OTg4MmM1MWU0YV8xMDU_31ecff08-ec66-456c-b353-ef714211e888">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="ie4de01ac93dc47218ac851e369b41796_D20221129-20221129"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5M2ViYjM2OWMyNTQzMTNhODYxNjJhNjdhMjZkNjFkL3NlYzpkOTNlYmIzNjljMjU0MzEzYTg2MTYyYTY3YTI2ZDYxZF8xL2ZyYWc6OWE3YTRkNzc1M2ZmNDlhMDk4YzIwNjk4ODJjNTFlNGEvdGV4dHJlZ2lvbjo5YTdhNGQ3NzUzZmY0OWEwOThjMjA2OTg4MmM1MWU0YV8yNjU_b07dfde8-af59-4102-87db-0bb0329cf424">2022-11-29</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="ie4de01ac93dc47218ac851e369b41796_D20221129-20221129"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5M2ViYjM2OWMyNTQzMTNhODYxNjJhNjdhMjZkNjFkL3NlYzpkOTNlYmIzNjljMjU0MzEzYTg2MTYyYTY3YTI2ZDYxZF8xL2ZyYWc6OWE3YTRkNzc1M2ZmNDlhMDk4YzIwNjk4ODJjNTFlNGEvdGV4dHJlZ2lvbjo5YTdhNGQ3NzUzZmY0OWEwOThjMjA2OTg4MmM1MWU0YV8yOTI_409b228e-ecf0-4517-b643-ac31574859c6">Allogene Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ie4de01ac93dc47218ac851e369b41796_D20221129-20221129"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5M2ViYjM2OWMyNTQzMTNhODYxNjJhNjdhMjZkNjFkL3NlYzpkOTNlYmIzNjljMjU0MzEzYTg2MTYyYTY3YTI2ZDYxZF8xL2ZyYWc6OWE3YTRkNzc1M2ZmNDlhMDk4YzIwNjk4ODJjNTFlNGEvdGFibGU6MjU1Y2Y1ODYwZTczNGJiNjgyYzJkODc1NGFlZTIxYzYvdGFibGVyYW5nZToyNTVjZjU4NjBlNzM0YmI2ODJjMmQ4NzU0YWVlMjFjNl8wLTAtMS0xLTQ0NTc5_5bff0afa-9acb-4315-8fa7-87c3bf29e4a9">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="ie4de01ac93dc47218ac851e369b41796_D20221129-20221129"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5M2ViYjM2OWMyNTQzMTNhODYxNjJhNjdhMjZkNjFkL3NlYzpkOTNlYmIzNjljMjU0MzEzYTg2MTYyYTY3YTI2ZDYxZF8xL2ZyYWc6OWE3YTRkNzc1M2ZmNDlhMDk4YzIwNjk4ODJjNTFlNGEvdGFibGU6MjU1Y2Y1ODYwZTczNGJiNjgyYzJkODc1NGFlZTIxYzYvdGFibGVyYW5nZToyNTVjZjU4NjBlNzM0YmI2ODJjMmQ4NzU0YWVlMjFjNl8wLTEtMS0xLTQ0NTc5_5ca06cd6-23d7-4aa6-bcbb-c74745ae6901">001-38693</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="ie4de01ac93dc47218ac851e369b41796_D20221129-20221129"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5M2ViYjM2OWMyNTQzMTNhODYxNjJhNjdhMjZkNjFkL3NlYzpkOTNlYmIzNjljMjU0MzEzYTg2MTYyYTY3YTI2ZDYxZF8xL2ZyYWc6OWE3YTRkNzc1M2ZmNDlhMDk4YzIwNjk4ODJjNTFlNGEvdGFibGU6MjU1Y2Y1ODYwZTczNGJiNjgyYzJkODc1NGFlZTIxYzYvdGFibGVyYW5nZToyNTVjZjU4NjBlNzM0YmI2ODJjMmQ4NzU0YWVlMjFjNl8wLTItMS0xLTQ0NTc5_5b932858-53a0-4be8-8d57-647ff511263e">82-3562771</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ie4de01ac93dc47218ac851e369b41796_D20221129-20221129"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5M2ViYjM2OWMyNTQzMTNhODYxNjJhNjdhMjZkNjFkL3NlYzpkOTNlYmIzNjljMjU0MzEzYTg2MTYyYTY3YTI2ZDYxZF8xL2ZyYWc6OWE3YTRkNzc1M2ZmNDlhMDk4YzIwNjk4ODJjNTFlNGEvdGV4dHJlZ2lvbjo5YTdhNGQ3NzUzZmY0OWEwOThjMjA2OTg4MmM1MWU0YV8zODA_e3cbb67a-bb15-46d5-a1bc-cd8dbecf5b9b">210 East Grand Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ie4de01ac93dc47218ac851e369b41796_D20221129-20221129"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5M2ViYjM2OWMyNTQzMTNhODYxNjJhNjdhMjZkNjFkL3NlYzpkOTNlYmIzNjljMjU0MzEzYTg2MTYyYTY3YTI2ZDYxZF8xL2ZyYWc6OWE3YTRkNzc1M2ZmNDlhMDk4YzIwNjk4ODJjNTFlNGEvdGV4dHJlZ2lvbjo5YTdhNGQ3NzUzZmY0OWEwOThjMjA2OTg4MmM1MWU0YV8zODQ_7471c548-bdec-400f-8d8f-0883c1892736">South San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ie4de01ac93dc47218ac851e369b41796_D20221129-20221129"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5M2ViYjM2OWMyNTQzMTNhODYxNjJhNjdhMjZkNjFkL3NlYzpkOTNlYmIzNjljMjU0MzEzYTg2MTYyYTY3YTI2ZDYxZF8xL2ZyYWc6OWE3YTRkNzc1M2ZmNDlhMDk4YzIwNjk4ODJjNTFlNGEvdGV4dHJlZ2lvbjo5YTdhNGQ3NzUzZmY0OWEwOThjMjA2OTg4MmM1MWU0YV8zODg_d927a179-47f9-40de-aeb2-a69e802d28d2">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ie4de01ac93dc47218ac851e369b41796_D20221129-20221129"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5M2ViYjM2OWMyNTQzMTNhODYxNjJhNjdhMjZkNjFkL3NlYzpkOTNlYmIzNjljMjU0MzEzYTg2MTYyYTY3YTI2ZDYxZF8xL2ZyYWc6OWE3YTRkNzc1M2ZmNDlhMDk4YzIwNjk4ODJjNTFlNGEvdGV4dHJlZ2lvbjo5YTdhNGQ3NzUzZmY0OWEwOThjMjA2OTg4MmM1MWU0YV8zOTE_f54e8b35-6398-4784-b7f4-0c8cfd1e8570">94080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ie4de01ac93dc47218ac851e369b41796_D20221129-20221129"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5M2ViYjM2OWMyNTQzMTNhODYxNjJhNjdhMjZkNjFkL3NlYzpkOTNlYmIzNjljMjU0MzEzYTg2MTYyYTY3YTI2ZDYxZF8xL2ZyYWc6OWE3YTRkNzc1M2ZmNDlhMDk4YzIwNjk4ODJjNTFlNGEvdGV4dHJlZ2lvbjo5YTdhNGQ3NzUzZmY0OWEwOThjMjA2OTg4MmM1MWU0YV81MDc_78c5eb78-89f0-4417-90ca-a4a5b7b51935">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ie4de01ac93dc47218ac851e369b41796_D20221129-20221129"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5M2ViYjM2OWMyNTQzMTNhODYxNjJhNjdhMjZkNjFkL3NlYzpkOTNlYmIzNjljMjU0MzEzYTg2MTYyYTY3YTI2ZDYxZF8xL2ZyYWc6OWE3YTRkNzc1M2ZmNDlhMDk4YzIwNjk4ODJjNTFlNGEvdGV4dHJlZ2lvbjo5YTdhNGQ3NzUzZmY0OWEwOThjMjA2OTg4MmM1MWU0YV81MTE_c7973ae2-374f-4402-aa51-fd96aa589289">457-2700</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="ie4de01ac93dc47218ac851e369b41796_D20221129-20221129"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5M2ViYjM2OWMyNTQzMTNhODYxNjJhNjdhMjZkNjFkL3NlYzpkOTNlYmIzNjljMjU0MzEzYTg2MTYyYTY3YTI2ZDYxZF8xL2ZyYWc6OWE3YTRkNzc1M2ZmNDlhMDk4YzIwNjk4ODJjNTFlNGEvdGFibGU6Y2Q5MzQ3OGYwMDIxNGUyNTkxZjAyOWNiZGRkZmNjMDcvdGFibGVyYW5nZTpjZDkzNDc4ZjAwMjE0ZTI1OTFmMDI5Y2JkZGRmY2MwN18wLTEtMS0xLTQ0NTc5_e49338ec-972d-4032-8faf-61e58e35e217">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="ie4de01ac93dc47218ac851e369b41796_D20221129-20221129"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5M2ViYjM2OWMyNTQzMTNhODYxNjJhNjdhMjZkNjFkL3NlYzpkOTNlYmIzNjljMjU0MzEzYTg2MTYyYTY3YTI2ZDYxZF8xL2ZyYWc6OWE3YTRkNzc1M2ZmNDlhMDk4YzIwNjk4ODJjNTFlNGEvdGFibGU6Y2Q5MzQ3OGYwMDIxNGUyNTkxZjAyOWNiZGRkZmNjMDcvdGFibGVyYW5nZTpjZDkzNDc4ZjAwMjE0ZTI1OTFmMDI5Y2JkZGRmY2MwN18xLTEtMS0xLTQ0NTc5_de100c34-1146-4762-b95c-3d88775c75dd">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="ie4de01ac93dc47218ac851e369b41796_D20221129-20221129"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5M2ViYjM2OWMyNTQzMTNhODYxNjJhNjdhMjZkNjFkL3NlYzpkOTNlYmIzNjljMjU0MzEzYTg2MTYyYTY3YTI2ZDYxZF8xL2ZyYWc6OWE3YTRkNzc1M2ZmNDlhMDk4YzIwNjk4ODJjNTFlNGEvdGFibGU6Y2Q5MzQ3OGYwMDIxNGUyNTkxZjAyOWNiZGRkZmNjMDcvdGFibGVyYW5nZTpjZDkzNDc4ZjAwMjE0ZTI1OTFmMDI5Y2JkZGRmY2MwN18yLTEtMS0xLTQ0NTc5_194d4503-0063-424e-9d17-09042ad7734b">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="ie4de01ac93dc47218ac851e369b41796_D20221129-20221129"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5M2ViYjM2OWMyNTQzMTNhODYxNjJhNjdhMjZkNjFkL3NlYzpkOTNlYmIzNjljMjU0MzEzYTg2MTYyYTY3YTI2ZDYxZF8xL2ZyYWc6OWE3YTRkNzc1M2ZmNDlhMDk4YzIwNjk4ODJjNTFlNGEvdGFibGU6Y2Q5MzQ3OGYwMDIxNGUyNTkxZjAyOWNiZGRkZmNjMDcvdGFibGVyYW5nZTpjZDkzNDc4ZjAwMjE0ZTI1OTFmMDI5Y2JkZGRmY2MwN18zLTEtMS0xLTQ0NTc5_dc428830-b742-49a2-bbf9-18ea65a2356a">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="ie4de01ac93dc47218ac851e369b41796_D20221129-20221129"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5M2ViYjM2OWMyNTQzMTNhODYxNjJhNjdhMjZkNjFkL3NlYzpkOTNlYmIzNjljMjU0MzEzYTg2MTYyYTY3YTI2ZDYxZF8xL2ZyYWc6OWE3YTRkNzc1M2ZmNDlhMDk4YzIwNjk4ODJjNTFlNGEvdGFibGU6NTBlMzczODQxYTg3NDU0Y2EzY2Q0NzczZDRmYTgzOWQvdGFibGVyYW5nZTo1MGUzNzM4NDFhODc0NTRjYTNjZDQ3NzNkNGZhODM5ZF8xLTAtMS0xLTQ0NTc5_a81525e1-70e7-419d-8590-8055f9580a66">Common&#160;Stock,&#160;$0.001&#160;par&#160;value&#160;per&#160;share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ie4de01ac93dc47218ac851e369b41796_D20221129-20221129"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5M2ViYjM2OWMyNTQzMTNhODYxNjJhNjdhMjZkNjFkL3NlYzpkOTNlYmIzNjljMjU0MzEzYTg2MTYyYTY3YTI2ZDYxZF8xL2ZyYWc6OWE3YTRkNzc1M2ZmNDlhMDk4YzIwNjk4ODJjNTFlNGEvdGFibGU6NTBlMzczODQxYTg3NDU0Y2EzY2Q0NzczZDRmYTgzOWQvdGFibGVyYW5nZTo1MGUzNzM4NDFhODc0NTRjYTNjZDQ3NzNkNGZhODM5ZF8xLTItMS0xLTQ0NTc5_e259b2cb-ce97-4933-95f3-8b924413583f">ALLO</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ie4de01ac93dc47218ac851e369b41796_D20221129-20221129"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5M2ViYjM2OWMyNTQzMTNhODYxNjJhNjdhMjZkNjFkL3NlYzpkOTNlYmIzNjljMjU0MzEzYTg2MTYyYTY3YTI2ZDYxZF8xL2ZyYWc6OWE3YTRkNzc1M2ZmNDlhMDk4YzIwNjk4ODJjNTFlNGEvdGFibGU6NTBlMzczODQxYTg3NDU0Y2EzY2Q0NzczZDRmYTgzOWQvdGFibGVyYW5nZTo1MGUzNzM4NDFhODc0NTRjYTNjZDQ3NzNkNGZhODM5ZF8xLTQtMS0xLTQ0NTc5_d230ba86-6ddb-4d89-9a7c-4c220eb16c1a">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="ie4de01ac93dc47218ac851e369b41796_D20221129-20221129"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5M2ViYjM2OWMyNTQzMTNhODYxNjJhNjdhMjZkNjFkL3NlYzpkOTNlYmIzNjljMjU0MzEzYTg2MTYyYTY3YTI2ZDYxZF8xL2ZyYWc6OWE3YTRkNzc1M2ZmNDlhMDk4YzIwNjk4ODJjNTFlNGEvdGV4dHJlZ2lvbjo5YTdhNGQ3NzUzZmY0OWEwOThjMjA2OTg4MmM1MWU0YV8xMTQ2_a4f81d39-481a-4a86-905a-f9947ec144cb">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>7
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MPNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4    "  E?'U5!T%-8H$   "Q
M$               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    (
M "5\?54Z6Z!J[0   "L"   1              "  :\   !D;V-0<F]P<R]C
M;W)E+GAM;%!+ 0(4 Q0    ( "5\?5697)PC$ 8  )PG   3
M  "  <L!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ )7Q]54)P
MY.]8!   KA   !@              ("!# @  'AL+W=O<FMS:&5E=',O<VAE
M970Q+GAM;%!+ 0(4 Q0    ( "5\?56?H!OPL0(  .(,   -
M  "  9H,  !X;"]S='EL97,N>&UL4$L! A0#%     @ )7Q]59>*NQS
M$P(   L              ( !=@\  %]R96QS+RYR96QS4$L! A0#%     @
M)7Q]5:K$(A8S 0  (@(   \              ( !7Q   'AL+W=O<FMB;V]K
M+GAM;%!+ 0(4 Q0    ( "5\?54D'INBK0   /@!   :              "
M ;\1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( "5\
M?55ED'F2&0$  ,\#   3              "  :02  !;0V]N=&5N=%]4>7!E
<<UTN>&UL4$L%!@     )  D /@(  .X3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="allo-20221129.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="allo-20221129.htm">allo-20221129.htm</File>
    <File>allo-20221129.xsd</File>
    <File>allo-20221129_lab.xml</File>
    <File>allo-20221129_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>12
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "allo-20221129.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "allo-20221129.htm"
     ]
    },
    "labelLink": {
     "local": [
      "allo-20221129_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "allo-20221129_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "allo-20221129.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "allo",
   "nsuri": "http://allogene.com/20221129",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20221129.htm",
      "contextRef": "ie4de01ac93dc47218ac851e369b41796_D20221129-20221129",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "role": "http://allogene.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20221129.htm",
      "contextRef": "ie4de01ac93dc47218ac851e369b41796_D20221129-20221129",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://allogene.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://allogene.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://allogene.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://allogene.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://allogene.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://allogene.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://allogene.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://allogene.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://allogene.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://allogene.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://allogene.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://allogene.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://allogene.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://allogene.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://allogene.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://allogene.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://allogene.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://allogene.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://allogene.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://allogene.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://allogene.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://allogene.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>13
<FILENAME>0001737287-22-000089-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001737287-22-000089-xbrl.zip
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M8MJU@FA-KZ("!<D<#M8+PS.D'9LT,CMR^GG?)"&EL%O2:F,*)4A=VM]32N#
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M4?.\5"HZJX<,@R*E9-++K-IK4679#V^I74PY+[-:RPJ/ATN+JL,K0<#&J1_
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MX7%WX NBW:*C;M[K^VFGZY@CC\@8#[/43NC+.0Z+WY8DURDZ#&"Y(1QCX)-
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M??T@<C" MZQ10MQR#8<B=BF\4F(CL]/(1IPUPXOPZ1^S+AYS13@"O0]C/[G
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MMZ8IW75;[FU?P 9NTXF\"?P9I,-@^_\ 4$L#!!0    ( "5\?564\NA79P(
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MYKVXLQ)^5U*< L%>XX,%AJYN;@:*SN?8!XZ+?):*M-2)P1],:S%ELVF<D"A
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M>Z7RD;EAT9]P%_+EXFTMZF\6S\0[R1L.=NYV=!_=:_ '._\#4$L! A0#%
M  @ )7Q]5?K:_1$%+P  KYH! !$              ( !     &%L;&\M,C R
M,C$Q,CDN:'1M4$L! A0#%     @ )7Q]593RZ%=G @  8@<  !$
M     ( !-"\  &%L;&\M,C R,C$Q,CDN>'-D4$L! A0#%     @ )7Q]531?
M4>-V"@  1%X  !4              ( !RC$  &%L;&\M,C R,C$Q,CE?;&%B
M+GAM;%!+ 0(4 Q0    ( "5\?54E9H%0I 8  -0P   5              "
M 7,\  !A;&QO+3(P,C(Q,3(Y7W!R92YX;6Q02P4&      0 !  $ 0  2D,
#

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
